Manufacturing Source Sample Clauses
The Manufacturing Source clause defines the specific location or facility where a product will be manufactured under a contract. It typically requires the supplier to disclose and, in some cases, obtain approval for the factory or site used for production, and may restrict changes to the manufacturing location without prior consent from the buyer. This clause ensures transparency and quality control by allowing the buyer to monitor production standards and manage risks related to unauthorized subcontracting or changes in manufacturing processes.
Manufacturing Source. The Borrowers shall establish a manufacturing source based in the United States (or such other location as is mutually agreed to by the Purchaser and the Borrowers), which source shall, within one hundred eighty (180) days following the Closing Date, deliver both a working senior unit and a working junior unit (in each instance, a prototype or a first article unit) to the Borrowers. The Borrowers shall, within two hundred seventy (270) days following the Closing Date, terminate all contracts, agreements and other arrangements with the Israeli manufacturing source.
Manufacturing Source. To the extent that upon the completion of Phase II of the Research Program Paravax owns, or leases pursuant to a long term lease, a manufacturing facility which has been approved by the United States Department of Agriculture or, if applicable, the United States Food and Drug Administration which allows Paravax to produce Canine Heartworm Vaccine for which regulatory approval or clearance for sale can be obtained in a specific country in the Territory, the parties shall proceed as though Paravax shall manufacture the Canine Heartworm Vaccine for distribution in that country by Bayer pursuant to the Distribution Agreement. To the extent that upon the completion of Phase II of the Research Program Paravax does not have such an approved manufacturing facility which allows it to produce Canine Heartworm Vaccine for which regulatory approval or clearance for sale can be obtained in a specific country, the parties shall proceed as though Bayer shall manufacture the Canine Heartworm Vaccine for distribution in that country by Bayer pursuant to the Distribution Agreement. Paravax may elect to forego or cease manufacture of Canine Heartworm Vaccine at any time, provided that Paravax gives Bayer adequate notice to allow Bayer, or a third party, to prepare for the manufacturing requirements of producing the Canine Heartworm Vaccine for, as applicable, Phases III ans IV of the Research Program and/or manufacture for commercial sale. After the commencement of Phase III of the Research Program, Paravax shall have no right to regain from Bayer the right to manufacture the Canine Heartworm Vaccine; however, Bayer agrees that is shall favorably consider any such request made by Paravax. In the event that Paravax elects to forego or cease manufacture of the Canine Heartworm Vaccine, Bayer shall be entitled to manufacture all of Bayer's requirements for Canine Heartworm Vaccine pursuant to the license described in Section 5.3 above.
Manufacturing Source. The Borrowers shall establish a manufacturing source based in the United States (or such other location as is mutually agreed to by the Purchaser and the Borrowers), which source shall, within one hundred and fifty (150) days following the Amendment No. 1 Waiver/Amendment Effective Date, deliver both a working senior unit and a working junior unit (in each instance, a prototype or a first article unit) to the Borrowers.”
(ii) Section 9.21 of the Purchase Agreement is hereby amended and restated in its entirety as follows:
Manufacturing Source. Notwithstanding anything contained in this Section 12.5, NaPro shall not have any obligation to provide to a Stand-By Manufacturing Source Confidential Information or technical support for the semi-synthetic manufacture of Bulk Drug.
Manufacturing Source. The Product will be manufactured by Manufacturer at its site located in Industria Vidriera 8▇, ▇▇▇▇▇. ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇, or another site proposed by Manufacturer that Licensee has been notified about in advance in writing by Manufacturer, and that has been expressly accepted by Licensee acceptance that shall not be unreasonably withheld, conditioned or delayed, provided such transfer does not result in a Supply Disruption. Any of the alternative sites proposed by Manufacturer shall comply with any applicable law. Manufacturer shall have the obligation at all times during the Term of this Agreement to obtain and maintain the government authorizations, permits, approvals and/or licenses required to enable Manufacturer to manufacture and, as the case may be, to import the Product as well as any and all raw materials and components used for the manufacture of the Products in the Territory and to provide such Product for shipment to Licensee to the location specified in Section 3.3 of this Agreement, in the understanding that Manufacturer shall assume and disburse all costs and fees associated with obtaining or maintenance of such government authorizations, permits, approvals and/or licenses.
Manufacturing Source. Licensee represents that the Licensed Products will be manufactured for Licensee by a person or entity who agrees to be bound by the terms hereof, and each shall sign the attached Schedule C prior to the manufacture of the Licensed Products pursuant to this Agreement. Equilink agrees during the Term not to disclose the name of such manufacturers (unless such names become known to the public other than by disclosure by Licensor) or contact such manufacturers other than through Licensee in connection with this Agreement.
Manufacturing Source. The Product will be manufactured by Manufacturer at its site located in Industria Vidriera 8▇, ▇▇▇▇▇. ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇, or another site proposed by Manufacturer that More Pharma has been notified about in advance in writing by Manufacturer, and that has been expressly accepted by More Pharma acceptance that shall not be unreasonably withheld, conditioned or delayed, provided such transfer does not result in a Supply Disruption. Any of the alternative sites proposed by Manufacturer shall comply with any applicable law. Manufacturer will provide such Product for shipment to More Pharma to the location specified in Section 3.2 of this Agreement.
Manufacturing Source. As partial consideration for the grant of the License, Racom hereby commits to engage Rohm as its primary manufacturing source for ferroelectric RFID products. Rohm shall have the first opportunity to supply Racom's needs for ferroelectric RFID products worldwide including both direct purchases by Racom from Rohm and indirect purchases made through Ramtron. As partial consideration for the grant of the License, Rohm commits to use its best efforts to supply Racom's ferroelectric RFID product manufacturing needs under most favorable commercial terms and with competitive quality, delivery and pricing. In addition to the rights granted in Section 2.1 above, during the term of this Agreement, Racom hereby grants to Rohm a royalty-free, non- exclusive, non-sublicensable, non-transferable right and license to use the Ferroelectric RFID Technology for the sole purpose of manufacturing for, and sale of ferroelectric RFID products exclusively to Racom.